Wave Life Sciences Ltd (NASDAQ:WVE) has priced its previously announced underwritten public offering of 20 million shares at $5.00 per share with approximately $100 million gross proceeds. In addition ...
CAMBRIDGE, Mass. and LONDON, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people ...
CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human ...
Additionally, GSK receives exclusive global license to Wave’s preclinical, potential first-in-class RNA editing program, WVE-006, to treat alpha-1 antitrypsin deficiency, a disease that impacts the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback